申请人:INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE)
公开号:US09193689B2
公开(公告)日:2015-11-24
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.
本发明涉及治疗化合物领域。更具体地,本发明涉及某些3-芳基-5-取代-2H-异喹啉-1-酮化合物,该化合物可以抑制PARP(例如PARP1,TNKS1,TNKS2等)和/或Wnt信号通路。本发明还涉及包含这些化合物的制药组合物,以及使用这些化合物和组合物在体内外抑制PARP(例如PARP1,TNKS1,TNKS2等);抑制Wnt信号通路;治疗通过抑制PARP(例如PARP1,TNKS1,TNKS2等)改善的疾病;治疗通过抑制Wnt信号通路改善的疾病;治疗增殖性疾病,如癌症等。